PharmaTimes April 19, 2024
Jen Brogan

Both will develop cancer vaccine candidates in selected haematological and solid tumour indications

CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines.

The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.

Solid tumour cancer, such as sarcoma, carcinoma and lymphoma, is characterised by an abnormal mass of tissue that usually does not contain cysts or liquid areas.

Haematologic cancer, otherwise known as blood cancer, including leukaemia, lymphoma and multiple myeloma, begins in blood-forming tissues such as the bone marrow or in the cells of the immune system.

...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Health System / Hospital, Partnerships, Provider, Trends
NHS Staff Survey Shows Less Burnout but Ongoing Concerns
Kaiser medical school receives initial accreditation
CHS' highest-earning executives in 2024
'We have to tell our story': How hospitals are fighting to protect Medicaid
Hospital margins hit 12-month high

Share This Article